The tyrosine kinase MerTK plays a prominent role in the body's immune response. MerTK signaling helps "calm" the body's first line of immunity, the macrophage, while it performs the routine duties - clearing cells that die ...
Jul 8, 2013
0
0
(Medical Xpress)—A new cancer drug designed to be effective in tumours with faulty BRCA genes has generated impressive responses in an early-stage clinical trial.
Jun 6, 2013
0
0
The HER2 growth-factor gene is known to be over-active in breast and gastro-esophageal cancers. But now, irregularities in the genes 's expression—among them mutations, amplifications, substitutions, and translocations—have ...
Jun 2, 2013
0
0
The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new Memorial Sloan-Kettering Cancer Center research presented ...
Jun 1, 2013
0
0
Many glioblastoma patients treated with bevacizumab (Avastin) have significant deterioration in neurocognitive function, symptoms and quality of life. Not only that, the changes often predict treatment outcomes, according ...
Jun 1, 2013
0
0
Intensity-modulated radiation therapy has become the most commonly used type of radiation in prostate cancer, but research from the University of North Carolina suggests that the therapy may not be more effective than older, ...
May 20, 2013
0
0
A device commonly used to treat dangerous heart rhythms may cause more issues for patients than a simpler version of the same device. The implantable cardioverter-defibrillator (ICD) prevents sudden cardiac death by detecting ...
May 14, 2013
0
1
A study led by prominent breast cancer experts from Europe and the US has revealed a number of potentially important prospects for targeted therapies, and brings opportunities of truly personalised therapy for breast cancer ...
May 2, 2013
0
0
The safety and preliminary efficacy of a new class of tumor fighting drugs were reported today by Scottsdale Healthcare's Virginia G. Piper Cancer Center Clinical Trials and the Translational Genomics Research Institute (TGen).
Apr 9, 2013
0
0
As many as three quarters of advanced ovarian cancer patients appeared to respond to a new two-step immunotherapy approach—including one patient who achieved complete remission—according research from the Perelman School ...
Apr 6, 2013
0
0
